Continued funding of the IBDWG is dependant upon CME/CE metrics reporting to supporters. If you find the IBDWG an interesting and useful site we would urge you to please remember to complete your applications for CME/CE credits after viewing accredited activities on the IBDWG. There is no fee for this. Should you not require the credits please could you complete the evaluation form at the end of the activity so we can evaluate the program more effectively. Many thanks in advance for you co-operation.
Audio presentations and a core slide library with comprehensive notes, plus ready-to-go presentations.
Ready-to-go Meeting Presentations
Unique diagnostic and therapeutic issues in pediatric inflammatory bowel disease (IBD)
Joel R. Rosh, MD, FAAP, FACG, AGAF
- Therapeutic algorithms for Crohn’s disease: Where are we in 2012?
Brian G. Feagan, MD
- Potential novel therapies - what's in the pipeline (AMA)
Jean-Frédéric Colombel, MD - Audio
Presentation: Discuss the role of the specialist gastroenterology nurse in answering frequently
posed questions raised by IBD patients
Laurie Powers, RN
View
all CME active Slide Libraries
Archive
(CME-expired materials)
Interactive case scenarios providing best practice solutions to common clinical issues.
- Pediatric inflammatory bowel disease: Making a timely diagnosis and instituting effective therapy
Joel R. Rosh, MD, FAAP, FACG, AGAF - Approaches to the
long-term management of ulcerative colitis: Optimizing therapeutic choices and patient outcomes
Bret Lashner, MD
View
all CME active Curbside Consults and Clinical Decision Maps
Expert commentary based on the latest published data with downloadable PowerPoint slides illustrating the key information.
- Coming Soon: Treating IBD early: Implications for mucosal healing and disease progression
William Sandborn, MD - IBS and IBD: Similar beginnings, but different endings?
Brian E. Lacy, PhD, MD - Recent advances in the management of mildly-to-moderately active ulcerative colitis
Bret A. Lashner, MD - The
use of prognostic markers to determine disease course and to improve management
Mark Silverberg, MD - Vaccinations and immunizations for patients with inflammatory bowel disease: Who, what, and when?
Gil Y. Melmed, MD, MS
Please provide us with your comments and feedback about this site.
Expert critiques of the most important recent publications in IBD.
Summarized by A. Hillary Steinhart, MD, MSc, FRCP(C)
This section is eligible for 0.75 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.
- Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.
- Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis.
- Meucci G, Fasoli R, Saibeni S, et al, on behalf of the IG-IBD. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: A prospective, multicenter study.
- Hoivik ML, Moum B, Solberg IC, et al, for the IBSEN Study Group. Health-related quality-of-life in patients with ulcerative colitis after a 10-year disease course: Results from the IBSEN study.
Summarized by Themistocles Dassopoulos, MD
This section is eligible for 0.75 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.
- Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD.
- 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: A population based study.
- Leblanc S, Allez M, Seksik P, et al. GETAID. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis.
- Yarur AJ, Deshpande AR, Pechman DM, et al. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events.
- Toedter G, Li K, Marano C, et al. Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis.
